Pacific Edge Ltd (ASX: PEB) Share Price and News

Mr Barclay has over 35 years of experience in business and 30 years healthcare experience. Tony was CFO at medical device company Fisher & Paykel Healthcare from the time of separation from Fisher & Paykel Appliances in 2001 until retiring from full-time employment in 2018. Prior to Fisher & Paykel Healthcare Tony worked for PriceWaterhouse and Arnott's Biscuits in finance roles. Tony is also a board member of listed company Rua Bioscience and holds several directorships in private companies, all in MedTech. He is the Chair of the Risk Committee and a member of the People and Culture Committee and the Capital and M&A Committee

Mr Masfen is the co-founder of Artemis Capital, a private equity investment firm based in Auckland. Following that he spent eight years with Air New Zealand (and later the merged entity with Ansett Australia) holding senior positions in Pricing, Revenue Management and Systems implementation. He holds directorships in numerous private companies and has knowledge of financial capital markets. She is a member of the People and Culture
Committee and Chair of the Capital and M&A Committee.

Dr Williams has held several governance roles, including with a NASDAQ listed biotech company and Chair of a Not-for-Profit Medical Informatics Company. Presently, he serves on boards of two Australian, and one American privately held biotechnology companies. He was co-founder of an American Biotechnology sold to J&J and currently co-founder and CSO of an American biotechnology company located in Los Angeles and Boston. Bryan was Director and CEO of the Hudson Institute of Medical Research. He is a member of the People and Culture Committee.

Ms Park has over 25 years of experience in corporate finance and capital markets. Her career includes roles with PwC in New Zealand and HSBC Investment Bank in London, as well as subsequent experience in investment management. Sarah co-founded Even Capital, a venture capital firm investing exclusively in female entrepreneurs across New Zealand and Australia. She is an experienced early-stage investor with a particular focus on healthcare. Sarah has governance experience, having held several board roles in different industries over the past 12 years. She is currently a member of the board of the Government Superannuation Fund Authority, National Provident Fund and Orbis Diagnostics. She is a member of the Risk Committee and a member of the Capital and M&A Committee.

Ms Stove is an experienced leader with more than 25 years of global executive and board experience across healthcare, biotechnology and regulated scientific sectors. She has a track record guiding organizations through growth, commercial transformation and complex regulatory environments, underpinned by commercial and scientific literacy. Her executive career spans senior leadership roles across Asia Pacific and Europe, culminating in her appointment as New Zealand General Manager for GlaxoSmithKline. Anna has held several governance roles including Chair of TAB NZ, Chair of Global Women NZ, Director of Medicines New Zealand, and Vice Chair of Shooting Star Children's Hospices in London. She is currently Chair of Rua Bioscience. She is Chair of the People and Culture Committee.

Me Green is a corporate finance professional, with approximately 25 years of experience in the Australasian capital, corporate and financial markets. He was an Executive Director for Investment Banking at Goldman Sachs where he worked for nearly 20 years and has been involved in many prominent New Zealand transactions including the IPOs of Meridian, Mighty River Power and Vector. Mark is a director of a number of entities including being Chair of The Better Product Group Limited and a Director of Mariposa Holdings. She is a member of Risk Committee and Chair of Capital and M&A Committee.

Mr Flood has spent more than 25 years in the global investment management industry having held senior Investment and Business Leadership roles in some of the investment management firms. His global perspective was honed through his years as a senior business leader and investor while working in London, Hong Kong and Singapore managing businesses, portfolios and teams of investors managing money on behalf of institutional investors from both the private as well as public sectors. Simon was a Managing Director at Merrill Lynch Investment Managers and COO of their Asian Business. He was Chief Investment Officer at Lion Global Investors, and prior to returning to New Zealand he was Head of Asia for AXA Investment Managers. She is a member of the Risk Committee and the Capital and M&A Committee.

-

-

-

-

-

-